The medication Zofenopril (Зокардис) is commonly used across conditions presenting with systemic imbalance to manage the chronic stress placed on the heart and arteries. The medicine is relevant for use in conditions such as essential high blood pressure and early care following acute myocardial infarction. The medication is applied in situations where additional management of discomfort is generally required.

---

Treatment of Essential High Blood Pressure

This domain covers the long-term management of conditions marked by increased physiological stress. The drug contributes to easing the overall symptom load by being used for managing the sustained reduction of chronic high blood pressure. This action assists with maintaining functional stability of the arteries and supports general well-being during symptomatic phases.

Quick Fact: Relief for Elevated Vascular Pressure This medicine is commonly used to help patients cope more steadily with the persistent symptoms related to heightened physiological activity in the circulatory system.

---

Early Care Following Acute Myocardial Infarction

Zofenopril is commonly used in clinical settings that involve acute or unstable symptom patterns, such as the critical phase following a heart attack. Applied during phases when symptoms become more noticeable, it contributes to improved comfort by being used to manage the risk of further functional strain and contributes to supporting functional stability of the heart. It may play a role in managing the risk of major cardiac events, such as severe congestive heart failure.

Eligibility Map: Who can and cannot use Zokardis — Official Regulatory Information

Zokardis (Zofenopril) eligibility is strictly defined by absolute contraindications and population-specific restrictions documented in official labeling. Use is generally allowed for Adults with essential high blood pressure or following an acute myocardial infarction, subject to specific exclusions.

Eligibility Status	Key Population Restrictions
Contraindicated	Patients with a history of Angioneurotic Oedema (from any ACE inhibitor), those with Severe Hepatic Impairment, and women in the second and third trimesters of pregnancy. Co-administration with Sacubitril/Valsartan or Aliskiren (in patients with diabetes or renal impairment) is prohibited.
Not Recommended	The pediatric population (under 18 years) due to unestablished safety and efficacy, patients in the first trimester of pregnancy, and those who are breastfeeding.
Conditional Use	Post-myocardial infarction patients who are 75 years of age or older require caution. Use is not established in post-MI patients with existing renal impairment, dialysis, or hepatic impairment.

The regulatory profile establishes that the medicine must not be used by patients with specific hypersensitivities or who are taking certain concomitant drugs. This structure ensures adherence to population constraints based on pre-existing medical history and organ function status.

Concomitant use of Zofenopril (the active ingredient in Зокардис) with several medicines may alter its effects or increase the risk of certain side effects.

Combinations Not Recommended or Contraindicated:

• Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The combination with Angiotensin Receptor Blockers (ARBs) or Aliskiren is generally not recommended, and is contraindicated in patients with diabetes or moderate-to-severe kidney impairment (GFR <60 mL/min/1.73 m^2).
• Lithium: Concomitant use is not recommended due to the potential for increased serum lithium levels and signs of toxicity.

Increased Risk of Hyperkalaemia (High Potassium Levels):

• The risk of hyperkalaemia is significantly increased with potassium-sparing diuretics (e.g., spironolactone, amiloride), potassium supplements, or potassium-containing salt substitutes.

Reduced Blood Pressure Control and Kidney Risk:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose aspirin (geq3 g/day), may reduce the blood pressure-lowering effect and increase the risk of worsening kidney function, especially in patients who are dehydrated or have existing kidney issues.

Other Important Interactions:

• Concomitant use with antidiabetic agents (oral or insulin) may increase the risk of low blood sugar (hypoglycaemia).
• Other medications that lower blood pressure, such as other diuretics, antipsychotics, or narcotics, may cause an excessive drop in blood pressure (hypotension).
• High incidence of anaphylactoid reactions has been reported during certain procedures, specifically haemodialysis with high-flux membranes and LDL apheresis with dextran sulphate.

Зокардис, containing the prodrug zofenopril, is converted in vivo to its active metabolite, zofenoprilat. Zofenoprilat functions as an inhibitor of the Angiotensin-Converting Enzyme (ACE), primarily located on the surface of endothelial cells within the vasculature, lungs, and kidneys.

By inhibiting ACE, zofenoprilat blocks the enzymatic conversion of the inactive decapeptide Angiotensin I to the potent octapeptide Angiotensin II. The resulting decrease in circulating and local Angiotensin II concentration leads to the reduction of its signaling through the Angiotensin II type 1 ( AT1) receptor. The diminished AT1 receptor activation causes vasodilation via reduced smooth muscle contraction, a decrease in the synthesis and release of aldosterone, and reduced systemic sodium and water retention. Additionally, ACE inhibition curtails the enzymatic degradation of the endogenous vasodilator bradykinin, leading to elevated systemic bradykinin levels. This rise in bradykinin further promotes vasodilation by stimulating the release of nitric oxide (NO) and prostaglandins from the endothelium. The resultant modulation of vascular tone and fluid balance culminates in a system-level decrease in peripheral vascular resistance and a reduction in intravascular volume.

How Зокардис (Zofenopril) is Used: Administration Guidelines

Zofenopril calcium is administered exclusively via the oral route as a film-coated tablet. The dosing strategy is determined by the condition being managed, involving distinct schedules for hypertension and for care following an acute myocardial infarction (AMI).

---

Administration and Dosage Regimens

The tablets can be taken flexibly before, during, or after meals. Dosing adheres to specific numerical parameters:

Condition	Starting Dose	Maintenance Dose	Maximum Dose	Frequency
Essential Hypertension	15 mg once daily	30 mg once daily	60 mg per day	Once daily
Acute Myocardial Infarction	7.5 mg twice daily	30 mg twice daily	N/A	Twice daily

For hypertension, the dose is typically adjusted every four weeks until the optimal maintenance dose is achieved. For AMI, the treatment is a six-week course initiated within 24 hours of symptom onset, with doses escalating according to a set time schedule (7.5 mg, 15 mg, and finally 30 mg twice daily).

---

Population-Specific Adjustments

Dosage reductions are required for certain patient groups. For hypertensive patients with moderate to severe kidney impairment or mild to moderate liver impairment, the starting and maintenance doses are reduced by half. Patients on dialysis receive one-quarter of the standard dose. The medicine is not recommended for use in the pediatric population as safety and efficacy have not been established.

Recent Clinical Evidence (Zofenopril)

The clinical evidence for Zofenopril (the active ingredient in Зокардис) is largely derived from the Survival of Myocardial Infarction Long-term Evaluation (SMILE) program, a series of randomized controlled trials (RCTs).

Acute Myocardial Infarction (AMI)

Core research in patients who experienced an acute myocardial infarction (heart attack) showed that the administration of Zofenopril, started within 24 hours of symptom onset and continued for six weeks, was associated with a reduction in the combined risk of death or severe congestive heart failure. Follow-up data indicated that this benefit was observed to persist for at least one year after the acute event.

Study Focus	Key Finding (Reported Outcome)
SMILE-1 RCT	Reported a reduced risk of death or severe congestive heart failure at six weeks compared to placebo.
SMILE-4 RCT	Investigated Zofenopril against another ACE inhibitor (ramipril) in patients with left ventricular dysfunction following AMI. Data reported a reduced occurrence of major cardiovascular events with Zofenopril plus standard therapy compared to the comparator plus standard therapy.

Hypertension and Other Subgroups

Studies have also examined the use of Zofenopril for the management of essential hypertension (high blood pressure), both as a single agent and in fixed-dose combination with a diuretic. These studies investigated the compound's blood pressure-lowering effect over time. Post-hoc analysis of the SMILE program further explored the impact of Zofenopril in patient subgroups, including those with metabolic syndrome, with findings suggesting that the compound's effect on major cardiovascular events was maintained in these higher-risk groups.

Common questions about Зокардис (FAQ)

---

Q: Are there any foods or drinks I need to avoid while taking Зокардис?

Official documents state that the tablet can be taken with or without food. However, official information specifically notes that potassium supplements and potassium-containing salt substitutes are interacting agents that should be avoided because their use is associated with an increased risk of high potassium levels in the blood. Patients are generally advised to discuss all dietary concerns with their prescriber.

---

Q: How often do I need to get lab tests while taking Зокардис?

Regulatory warnings indicate that patients taking this medicine require monitoring. This typically includes checking kidney function, blood pressure, and the level of electrolytes in the blood, such as potassium. The frequency of these necessary monitoring tests is determined by the healthcare provider.

---

Q: Why should I avoid salt substitutes while taking Зокардис?

This caution is directly related to the risk of hyperkalaemia, which is the term for a rise in potassium levels in the blood. Salt substitutes often contain potassium chloride, and since this medicine can also affect the body's potassium balance, their use is associated with an increased risk of hyperkalaemia.

---

Q: What should I know about taking Зокардис before a blood test or operation?

Official product information notes the importance of disclosing use of this medicine to healthcare professionals, such as an anaesthetist before surgery. This information assists in appropriate blood pressure management during the procedure. This is relevant to any procedure involving general anaesthesia.

---

Q: Is it safe to use Зокардис if I have diabetes?

Official documents indicate that special caution and close monitoring of kidney function and blood electrolytes are necessary for patients with diabetes, especially those with diabetes-related kidney problems. Furthermore, the official label notes an interaction warning with antidiabetic agents that may lead to an increased risk of low blood sugar.

---

Q: Can I take Зокардис if I have recently had surgery?

Official label information indicates that disclosure of taking the medicine to an anaesthetist is recommended before receiving anaesthesia for an operation. This information is relevant to the required medical considerations when the medicine is used around the time of an operation.

---

Q: Does the time of day matter for taking Зокардис?

Official administration guidelines usually suggest taking the tablet at a consistent time each day to help maintain stable therapeutic effects. This consistency is generally considered more important than the specific hour of the day. Flexibility exists regarding whether it's taken with or without food.

---

Q: Why do some people have to start taking Зокардис with a very small dose?

Dosage reductions are instructed in official guidelines for specific patient groups, including those with moderate to severe kidney impairment or mild to moderate liver impairment. This adjustment is necessary to account for the body's potentially altered ability to process the medicine and minimize exposure risks.

---

Q: Can Зокардис cause changes in taste?

Changes in taste, medically known as dysgeusia, have been reported as an adverse reaction with medicines belonging to the same pharmacological class as Зокардис (ACE inhibitors). This is a known, though not necessarily common, safety finding related to the mechanism of action.

---

Q: What period of studies does the evidence base for Зокардис cover?

The main body of clinical research, known as the SMILE program, involved randomized controlled trials where patients were followed up and treated for an extended period. The data used for analysis covered treatment periods ranging from six to 48 weeks, establishing the basis for the approved uses.

---

Q: Is there a risk of high potassium in the blood from taking Зокардис?

High levels of potassium in the blood, or hyperkalaemia, are a recognized risk associated with medicines in the ACE inhibitor class. The official label notes that pre-existing high potassium levels necessitate medical monitoring and caution.

---

Q: Does Зокардис interact with alcohol?

Yes, official warnings state that alcohol increases the blood pressure-lowering effect of the medicine. This excessive drop in blood pressure is known as hypotension.

How to Store and Dispose of Zocardis

Official regulatory documents define specific requirements for the storage, handling, and disposal of Zocardis (zofenopril calcium) to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C (Do not store above 30°C).
Protection	Keep in the original package to protect the medicine from moisture.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability	Do not use Zocardis after the expiry date stated on the packaging.

Disposal Instructions

Regulatory instructions state that Zocardis must not be disposed of via household waste or wastewater. To protect the environment, the user must consult a pharmacist for the proper method of disposing of medicines that are no longer required or have expired.